Who Should Avoid GLP-1 Injectables?

The Short Answer: Who Should Not Use GLP-1 Injectables?

GLP-1 receptor agonists are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2, active pancreatitis, or current pregnancy. Beyond those hard stops, several groups carry enough added risk that prescribing requires extra caution, dose modification, or specialist co-management.

The FDA prescribing information for semaglutide injection carries a boxed warning: "Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice" [1]. That warning applies equally to liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and tirzepatide (Mounjaro, Zepbound) [2][3][4].

Understanding why each group faces elevated risk helps patients and clinicians make better-informed decisions about whether to proceed, wait, or choose an alternative.

Absolute Contraindications: The Hard No List

Medullary Thyroid Carcinoma (Personal or Family History)

Medullary thyroid carcinoma arises from calcitonin-secreting C-cells of the thyroid gland. GLP-1 receptors are expressed on those same C-cells, and rodent data show dose-dependent C-cell hyperplasia and carcinoma after sustained GLP-1 agonist exposure [5]. Whether this translates to humans remains under active investigation, but the FDA has concluded the theoretical risk is sufficient for a black-box contraindication [1].

Anyone with a personal history of MTC should not use any injectable GLP-1 agonist. The same restriction applies if a first-degree relative (parent, sibling, child) has had MTC, because familial MTC follows an autosomal dominant pattern linked to RET proto-oncogene mutations [5].

Baseline calcitonin measurement is not required by labeling but is recommended by the American Thyroid Association for patients starting long-term GLP-1 therapy who have thyroid nodules or a family history of thyroid disease [6].

Multiple Endocrine Neoplasia Type 2 (MEN2)

MEN2 is a hereditary syndrome caused by activating RET mutations. It predisposes carriers to MTC, pheochromocytoma, and parathyroid adenoma. Because MTC is a defining feature of MEN2A and MEN2B, the boxed warning for GLP-1 agonists explicitly names both conditions [1][2].

Genetic testing for RET mutations is now standard before thyroid surgery in suspected MTC, and a confirmed or suspected MEN2 diagnosis is a categorical contraindication regardless of current calcitonin levels [6].

Active or Chronic Pancreatitis

Acute pancreatitis has been reported in GLP-1 clinical programs. The FDA reviewed postmarketing safety data and updated labeling for all GLP-1 classes to reflect this risk [7]. The mechanism may involve increased pancreatic ductal pressure or direct trophic effects on acinar cells, though causality remains debated in the literature [8].

The prescribing information for semaglutide states: "If pancreatitis is suspected, semaglutide should be discontinued and not restarted if pancreatitis is confirmed" [1]. Patients with a prior episode of acute pancreatitis, or with chronic pancreatitis from any cause (alcohol, gallstones, genetic), should not start GLP-1 therapy without a gastroenterology consultation confirming remission and an explicit risk-benefit discussion [7].

A 2014 NEJM analysis of the SAVOR-TIMI 53 trial found no statistically significant increase in pancreatitis with saxagliptin, a related incretin drug, but GLP-1 agonists and DPP-4 inhibitors differ mechanistically, and clinical vigilance remains the standard of care [9].

Pregnancy and Breastfeeding

Pregnancy

GLP-1 agonists are not approved for use during pregnancy. Animal reproduction studies with semaglutide at exposures 0.4 to 7 times the maximum recommended human dose showed embryo-fetal mortality and structural abnormalities [1]. No adequate, well-controlled human trials exist in pregnant women.

Novo Nordisk maintains a pregnancy exposure registry (1-800-727-6500) for semaglutide, and the FDA label advises discontinuation at least two months before a planned pregnancy because of the drug's long half-life (approximately seven days for semaglutide) [1]. For weekly subcutaneous tirzepatide, Eli Lilly similarly advises stopping at least one month before attempting conception [3].

Women of reproductive age who use GLP-1 agonists should discuss reliable contraception with their prescriber.

Breastfeeding

Published pharmacokinetic data on GLP-1 agonists in human breast milk are absent. Because potential harm to a nursing infant cannot be excluded, current labeling for semaglutide and tirzepatide advises against use while breastfeeding [1][3].

High-Risk Groups Requiring Extra Caution

Chronic Kidney Disease (CKD)

GLP-1 agonists are not renally cleared in the traditional sense, but nausea, vomiting, and reduced oral intake can trigger volume depletion and precipitate acute kidney injury (AKI) in patients with existing CKD [10]. The FDA label for semaglutide injection notes postmarketing reports of AKI, some requiring dialysis, in patients who experienced GI side effects [1].

The 2023 FLOW trial (N=3,533) demonstrated that semaglutide 1.0 mg weekly reduced the composite kidney-disease outcome by 24% versus placebo in people with type 2 diabetes and CKD, suggesting potential benefit, but patients enrolled had estimated GFR of 50 to 75 mL/min/1.73m² and were closely monitored [11]. Patients with GFR <30 mL/min/1.73m² were excluded from most registration trials and require individualized assessment [11].

Dose-titration should be slower in CKD, adequate hydration must be maintained, and serum creatinine should be checked at one and three months after starting therapy.

Gastroparesis and Serious GI Motility Disorders

GLP-1 receptor agonists slow gastric emptying. That property contributes to satiety and postprandial glucose control, but it also worsens pre-existing gastroparesis [12]. The American Neurogastroenterology and Motility Society issued a clinical update in 2023 flagging GLP-1 agonists as a potential trigger for gastroparesis symptom exacerbation, particularly at higher doses [12].

Patients with a confirmed diagnosis of diabetic or idiopathic gastroparesis, or with a history of bowel obstruction, should discuss the risk thoroughly with a gastroenterologist before starting these agents. Imaging protocols (endoscopy, colonoscopy) performed under anesthesia now routinely ask about GLP-1 use because residual gastric content increases aspiration risk even after standard fasting [13].

The American Society of Anesthesiologists published guidance in 2023 recommending that patients on GLP-1 agonists hold the drug for one dosing cycle before elective procedures requiring general anesthesia, and consider a liquid diet for 24 hours before the procedure [13].

Hypoglycemia Risk: Insulin and Sulfonylurea Co-Administration

GLP-1 agonists do not cause hypoglycemia by themselves in people without diabetes; their insulin-secreting action is glucose-dependent. However, combining a GLP-1 agonist with basal insulin or a sulfonylurea (glipizide, glimepiride, glyburide) creates additive hypoglycemia risk [2][14].

In the SUSTAIN-5 trial (N=397), adding semaglutide 0.5 mg or 1.0 mg to basal insulin required a mean basal insulin dose reduction of 20% to avoid hypoglycemia [14]. Prescribers must proactively lower the sulfonylurea or insulin dose at the time GLP-1 therapy is initiated, not wait for symptomatic hypoglycemia to occur [2].

Patients on insulin should own and use a glucometer. Those on a sulfonylurea alone may warrant a switch to a GLP-1-compatible alternative before combination therapy begins.

Diabetic Retinopathy

Rapid glucose lowering with semaglutide has been linked to early worsening of diabetic retinopathy in patients with pre-existing disease. In SUSTAIN-6 (N=3,297), semaglutide-treated patients showed a higher rate of retinopathy complications versus placebo (3.0% vs. 1.8%, P<0.001) in a population that started with high baseline HbA1c [15]. The effect mirrors a phenomenon documented after rapid glycemic correction with intensive insulin, likely reflecting transient changes in retinal perfusion [15].

Patients with known proliferative diabetic retinopathy or severe nonproliferative retinopathy should have a retinal examination before starting GLP-1 therapy and at regular intervals thereafter. An ophthalmology referral is appropriate before initiating therapy in high-risk patients [6].

Eating Disorders

Anorexia nervosa, bulimia nervosa, and binge-eating disorder are not listed as formal contraindications in FDA prescribing information, but clinical guidelines from the American Psychiatric Association and leading obesity medicine societies recommend psychiatric clearance before using appetite-suppressing agents in this population [16].

GLP-1 agonists reduce hunger, slow gastric emptying, and can intensify restrictive behaviors in patients with anorexia. Conversely, in binge-eating disorder, suppression of appetite may sometimes be beneficial, but only under coordinated psychiatric and medical management. Prescribers should screen for eating disorder history using a validated tool (e.g., SCOFF questionnaire) before initiating therapy [16].

Heart Failure With Reduced Ejection Fraction (HFrEF)

The evidence here is nuanced. Liraglutide was associated with increased heart rate and adverse outcomes in a small heart-failure trial (FIGHT, N=300), and the FDA label notes that GLP-1 agonists increase resting heart rate by approximately two to three beats per minute on average [17]. For most patients, this is clinically irrelevant, but in HFrEF patients already managing arrhythmia risk, even modest chronotropic effects warrant discussion.

Tirzepatide showed neutral cardiovascular outcomes in SURMOUNT-MMO (ongoing as of this writing), and semaglutide showed cardiovascular benefit in the SELECT trial (N=17,604) in people with overweight or obesity without diabetes [18]. Cardiology co-management is advisable in New York Heart Association Class III or IV HF patients considering GLP-1 therapy.

Special Populations: Additional Considerations

Age Under 18

Semaglutide subcutaneous injection (Wegovy) received FDA approval in December 2022 for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex) [19]. Liraglutide (Saxenda) is approved for ages 12 and up as well. Other GLP-1 agonists, including tirzepatide, do not yet carry pediatric approvals. Prescribing off-label GLP-1 agonists to children under 12 is not supported by trial evidence and should not occur outside a research protocol [19].

Older Adults (Age 75 and Above)

Older adults tolerate GLP-1 agonists reasonably well, but their lower baseline muscle mass means weight loss can accelerate sarcopenia if protein intake and resistance exercise are not emphasized [20]. A 2023 analysis of STEP-1 data (N=1,961) found similar weight-loss efficacy in older participants but higher rates of nausea requiring dose adjustment [20]. Renal function declines with age, making hydration monitoring more important in this group.

Thyroid Disease (Non-MTC)

Hypothyroidism or hyperthyroidism from Hashimoto's disease or Graves' disease is not a contraindication to GLP-1 therapy. Thyroid function should be stable and managed before starting, because uncontrolled thyroid disease complicates metabolic interpretation and can mimic or mask GLP-1 side effects such as palpitations, fatigue, and GI symptoms [6].

The HealthRX clinical team uses a four-domain pre-prescribing checklist before initiating any GLP-1 agonist: (1) thyroid and MEN2 history screening, (2) pancreatic risk assessment including alcohol use, gallstones, and prior lipase elevation, (3) GI motility review including prior gastroparesis diagnosis and planned surgeries, and (4) medication reconciliation focused on insulin, sulfonylureas, and oral contraceptives whose absorption may be affected by slowed gastric emptying. Patients who clear all four domains proceed to a 30-day starter dose; those who flag one or more domains undergo specialist co-management before initiation.

Drug-Drug Interactions That Create Risk

Oral Medications With Narrow Therapeutic Windows

Slowed gastric emptying reduces the peak absorption (Cmax) and delays time-to-peak (Tmax) of orally administered drugs. This matters most for medications with narrow therapeutic windows: levothyroxine, cyclosporine, tacrolimus, warfarin, and certain oral contraceptives [1][21].

Patients on levothyroxine should take it 30 to 60 minutes before eating and well before their GLP-1 injection day. TSH should be rechecked six to eight weeks after starting a GLP-1 agonist because altered absorption can shift thyroid hormone levels enough to require dose adjustment [6][21].

Warfarin INR can fluctuate as diet and gastric transit change. Increased INR monitoring is warranted during the first two to three months of GLP-1 therapy in anticoagulated patients [21].

Alcohol

Alcohol is not a pharmacokinetic interaction partner with GLP-1 agonists, but it is a known risk factor for pancreatitis and hypoglycemia. Patients who drink heavily are both at higher pancreatitis risk from GLP-1 therapy and less reliable in recognizing GI warning signs [8]. Clinical screening for alcohol use disorder (AUDIT-C questionnaire) is appropriate before prescribing [8].

What the Labeled Indication Actually Requires

FDA-approved indications for GLP-1 agonists used in weight management specify:

• Wegovy (semaglutide 2.4 mg weekly): adults with initial BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) [1].
• Zepbound (tirzepatide 2.5 mg to 15 mg weekly): same BMI thresholds as Wegovy [3].
• Saxenda (liraglutide 3.0 mg daily): adults with BMI of 30 or above, or 27 or above with comorbidity; approved for ages 12 and up with obesity [2].

Prescribing outside these indications is legal but off-label. Patients with BMI <27 without a qualifying comorbidity receiving compounded semaglutide or tirzepatide from telehealth platforms are taking a medication that has not been studied at their metabolic baseline, and the risk-benefit ratio is different from the trial populations [1][3].

When to Stop a GLP-1 Agonist Already in Use

Stopping criteria matter as much as starting criteria. A patient who develops any of the following during therapy should discontinue and seek prompt evaluation:

• Persistent severe abdominal pain radiating to the back (possible pancreatitis). Lipase and amylase should be drawn; if elevated more than three times the upper limit of normal, discontinue permanently [7].
• A new thyroid nodule or elevated calcitonin on routine testing [6].
• Severe or recurrent hypoglycemia despite reducing co-administered secretagogue doses [14].
• Onset or rapid worsening of diabetic retinopathy symptoms [15].
• Signs of AKI: rising creatinine, reduced urine output, or edema, particularly in the context of protracted nausea and vomiting [10][11].

Temporary holds are also appropriate before elective surgery, planned pregnancy, or severe acute illness where oral intake is compromised.